Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
Denali Therapeutics (DNLI) Stock Price & Analysis
388 Followers
DNLI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.24 - $39.43
Previous Close$23.27
Volume41.77K
Average Volume (3M)675.83K
Market Cap
$3.16B
Enterprise Value$1.90B
Total Cash (Recent Filing)$1.34B
Total Debt (Recent Filing)$60.35M
Price to Earnings (P/E)-9.0
Beta1.36
Next Earnings
Nov 02, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.59
Shares Outstanding136,677,646
10 Day Avg. Volume747,858
30 Day Avg. Volume675,826
Standard Deviation0.19
R-Squared0.15
Alpha0.00920
Financial Highlights & Ratios
Price to Book (P/B)3.00
Price to Sales (P/S)28.86
Price to Cash Flow (P/CF)10.60
P/FCF Ratio-11.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.56
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.77
Forecast
1Y Price Target
$57.33Price Target Upside147.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Denali Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $20.24 and its highest was $39.43 in the past 12 months.
What is Denali Therapeutics’s market cap?
Currently, no data Available
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Nov 02, 2023 which is in 219 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Feb 27, 2023. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.788 by $0.038.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 136,677,640 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.788. Following the earnings report the stock price went up 1.268%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Among the largest hedge funds holding Denali Therapeutics’s share is Flagship Pioneering Inc.. It holds Denali Therapeutics’s shares valued at 73M.
---
Denali Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.33 (147.75% Upside)
$57.33 (147.75% Upside)
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 17.6%
Last 30 Days ▲ 17.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.90%
12-Months-Change
Fundamentals
Return on Equity
-32.52%
Trailing 12-Months
Asset Growth
3.99%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Denali Therapeutics
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
---
Top 5 ETFs holding DNLI
Fidelity Nasdaq Composite Index ETF
$972.58K
Vanguard ESG U.S. Stock ETF
$458.19K
Strive 1000 Growth ETF
$687.30
Up to five ETFs with an Outperform Smart Score that hold DNLI. The ETFs are listed according to market value of DNLI within the ETF
---
---